← Leaderboards
Ruiwen Zhang
University Of Alabama At Birmingham
$8,951,488
Attributed
$8,951,488
Total exposure
6
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1.1M · FY2005–21$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
Funding mix
By agency
NIH$8,951,488 · 6
By mechanism
R01$8,671,112 · 5
N01$280,376 · 1
Top collaborators
No co-investigators on record.
Most similar at University Of Alabama At Birmingham
Same institution · by research overlap
- Edward E Partridge$43,798,134
- Ralph R Weichselbaum$16,065,057
- Barry P Sleckman$19,849,738
- Stephen Barnes$26,295,575
- Richard J. Whitley$15,110,969
Others in their field
Top investigators on “Oncogenes”
- Ralph Parchment · Leidos Biomedical Research, Inc.$141,315,269
- David Heimbrook · Leidos Biomedical Research, Inc.$73,747,183
- Scott W Lowe · Sloan-Kettering Inst Can Research$36,382,798
- John Blenis · Harvard University (Medical School)$29,103,255
- Andrea Califano · Columbia University Health Sciences$28,006,523
- Robert Neil Eisenman · Fred Hutchinson Cancer Research Center$27,166,845
Research focus
OncogenesIn VivoIn VitroMdm2 GeneMolecularDesignResponseIn Vivo ModelAntineoplastic AgentsBaseGenesGeneticPathway InteractionsOverexpressionPropertyInhibitor/AntagonistMediatingCancer CellMalignant NeoplasmsCancer TherapyDrug KineticsTherapeutic AgentsProgramsTp53 Gene
Grant awards (27)
Novel NFAT1-MDM2 inhibitor for Breast Cancer Therapy$578,917
R01 · FY2021 · CA · contact PI
Novel NFAT1-MDM2 inhibitor for Breast Cancer Therapy$578,917
R01 · FY2020 · CA · contact PI
Novel NFAT1-MDM2 inhibitor for Breast Cancer Therapy$561,548
R01 · FY2019 · CA · contact PI
Novel NFAT1-MDM2 inhibitor for Breast Cancer Therapy$578,917
R01 · FY2018 · CA · contact PI
Novel Small Molecule MDM2 Inhibitors for Pancreatic Cancer Therapy$491,695
R01 · FY2018 · CA · contact PI
Novel NFAT1-MDM2 inhibitor for Breast Cancer Therapy$592,167
R01 · FY2017 · CA · contact PI
Novel Small Molecule MDM2 Inhibitors for Pancreatic Cancer Therapy$289,024
R01 · FY2017 · CA · contact PI
Novel Small Molecule MDM2 Inhibitors for Pancreatic Cancer Therapy$191,455
R01 · FY2017 · CA · contact PI
Novel Small Molecule MDM2 Inhibitors for Pancreatic Cancer Therapy$480,479
R01 · FY2016 · CA · contact PI
Novel Small Molecule MDM2 Inhibitors for Pancreatic Cancer Therapy$499,495
R01 · FY2015 · CA · contact PI
Novel Small Molecule MDM2 Inhibitors for Pancreatic Cancer Therapy$497,021
R01 · FY2014 · CA · contact PI
Dietary Chemopreventive Components/Oncogene Interaction and Cancer$273,686
R01 · FY2011 · CA · contact PI
Dietary Chemopreventive Components/Oncogene Interaction and Cancer$275,500
R01 · FY2010 · CA · contact PI
Preclinical Pharmacological Studies of Antitumor and Other Therapeutic Agents$25,000
N01 · FY2010 · CA · contact PI
Dietary Chemopreventive Components/Oncogene Interaction and Cancer$275,500
R01 · FY2009 · CA · contact PI
Preclinical Pharmacological Studies of Antitumor and Other Therapeutic Agents$255,376
N01 · FY2009 · CA · contact PI
MDM2 AS A NEGATIVE REGULATOR OF P21 WAF1/CIP1$145,536
R01 · FY2009 · CA · contact PI
MDM2 AS A NEGATIVE REGULATOR OF P21 WAF1/CIP1$109,000
R01 · FY2009 · CA · contact PI
Dietary Chemopreventive Components/Oncogene Interaction and Cancer$275,500
R01 · FY2008 · CA · contact PI
MDM2 AS A NEGATIVE REGULATOR OF P21 WAF1/CIP1$254,536
R01 · FY2008 · CA · contact PI
Dietary Chemopreventive Components/Oncogene Interaction and Cancer$275,500
R01 · FY2007 · CA · contact PI
MDM2 AS A NEGATIVE REGULATOR OF P21 WAF1/CIP1$254,536
R01 · FY2007 · CA · contact PI
MDM2 AS A NEGATIVE REGULATOR OF P21 WAF1/CIP1$262,139
R01 · FY2006 · CA · contact PI
MDM2 AS A NEGATIVE REGULATOR OF P21 WAF1/CIP1$267,064
R01 · FY2005 · CA
MDM2 ONCOGENE AS A TARGET FOR MODULATING CANCER THERAPY$227,557
R01 · FY2002 · CA
MDM2 ONCOGENE AS A TARGET FOR MODULATING CANCER THERAPY$220,928
R01 · FY2001 · CA
MDM2 ONCOGENE AS A TARGET FOR MODULATING CANCER THERAPY$214,495
R01 · FY2000 · CA